News
Sarepta shares slump
Digest more
Sarepta Therapeutics, Inc. faces setbacks with Elevidys, safety issues, and workforce cuts, raising concerns about its ...
Sarepta Therapeutics appears to have right-sized itself after laying off over a third of its staff, announcing a significant ...
Sarepta agrees to FDA's black box warning and announces major restructuring, including job cuts and cost-saving measures to ...
On a conference call, CEO Doug Ingram said the decision to cut 36% of the company's staff and halt several drug programs was ...
Sarepta stock surged after the pharma company said it would lay off a third of its workforce and add a black-box warning to ...
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced a strategic restructuring plan ...
The drastic cost-cutting move follows the deaths of two teenagers that forced the company to restrict usage of its gene ...
Sarepta's cost-saving moves, FDA surprises, and pipeline potential position SRPT as a unique opportunity. Read here for an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback